An independent source of information on U.S. brand name drugs for health professionals

Drugdocs Logo

An independent source of information on U.S. brand name drugs for health professionals

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Sogroya

Chemical Namesomapacitan-beco
Dosage FormInjection (subcutaneous; 10 mg/1.5 mL, 6.7 mg/mL)
Drug ClassHormones
SystemEndocrine
CompanyNovo Nordisk Inc.
Approval Year2020

Indication

  • For replacement of growth hormone in adults with growth hormone deficiency (GHD).
Last updated on 12/9/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Sogroya (somapacitan-beco) Prescribing Information. 2020Novo Nordisk Inc., Plainsboro, NJ
Document TitleYearSource
Once-weekly somapacitan is effective and well tolerated in adults with GH Deficiency: a randomized phase 3 trial. 2020The Journal of Clinical Endocrinology & Metabolism
Similar safety and efficacy in previously treated adults with growth hormone deficiency randomized to once‐weekly somapacitan or daily growth hormone. 2020Clinical Endocrinology